8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 11, 2026·SEC
Material company update
May 7, 2026·SEC
Apyx Medical Corporation(APYX)Earnings, Financials & Key Ratios
APYX•NASDAQ
$4.20
Price updated Jul 7, 2026
AboutApyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Show more
- Revenue$53M+9.9%
- EBITDA-$6M+68.3%
- Net Income-$11M+52.2%
- EPS (Diluted)-0.27+59.1%
- Gross Margin36.02%-41.0%
- EBITDA Margin-10.96%+71.1%
- Operating Margin-12.2%+68.9%
- Net Margin-21.22%+56.5%
- ROE-76.88%+32.4%
APYX Price & Volume
Apyx Medical Corporation (APYX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Threaten Long-Term Solvency
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Persistent operating margin deficits
Key Thesis Takeaways
- Apyx Medical faces a challenging path to profitability as it struggles to convert revenue growth into sustainable operating margins, evidenced by a -7.3% operating margin in 2026Q1.
- The company's reliance on debt financing, with a debt-to-equity ratio that has climbed to 3.02, creates significant financial strain as the equity base continues to erode.
- Investors should monitor the company's ability to stabilize its volatile gross margins, which swung from -10.5% in 2025Q4 to 37.4% in 2026Q1, before considering any long-term position.
Verdict Logic
the company's persistent cash burn and an accumulated deficit of $91.2 million as of 2026Q1 suggest that the current business model lacks a clear path to self-sustaining profitability.
APYX Growth Metrics
Apyx Medical Corporation (APYX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years6%
5 Years13.78%
3 Years5.89%
TTM18.22%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM54.24%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM60.95%
Return on Capital
10 Years-26.07%
5 Years-29.77%
3 Years-25.16%
Last Year-11.8%
APYX Recent Earnings
Apyx Medical Corporation (APYX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.05+54.5%
$0.11
Rev
$12M+18.7%
$11M
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.03+50.0%
$0.06
Rev
$19M+3.4%
$19M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.05+16.7%
$0.06
Rev
$13M-28.9%
$18M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.09+3.6%
$0.09
Rev
$11M-2.8%
$12M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.05vs $0.11+54.5% | $12Mvs $11M+18.7% |
| Q2 2026 | Mar 10, 2026 | $0.03vs $0.06+50.0% | $19Mvs $19M+3.4% |
| Q4 2025 | Nov 6, 2025 | $0.05vs $0.06+16.7% | $13Mvs $18M-28.9% |
| Q3 2025 | Aug 7, 2025 | $0.09vs $0.09+3.6% | $11Mvs $12M-2.8% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Apyx Medical Corporation (APYX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.20 | $175.87M | -15.56 | 9.86% | -21.22% | -76.88% | — | |
| $0.12 | $705.41K | -0.09 | -8.54% | -21.13% | -360.33% | — | |
| $0.25 | $29.63M | -16.07 | 2.68% | -10.76% | -77.48% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $7.41 | $92.58M | -29.64 | 14.52% | -9.05% | -70.95% | — | |
| $14.54 | $921.24M | 10.17 | -6.16% | 23.27% | 13.28% | — |
Compare APYX vs Peers
Apyx Medical Corporation (APYX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
APYX SEC Filings & Documents
Apyx Medical Corporation (APYX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when APYX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
APYX Frequently Asked Questions
Apyx Medical Corporation (APYX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Apyx Medical Corporation's revenue?
Apyx Medical Corporation (APYX) reported $55.9M in revenue for fiscal year 2025. This represents a 647% increase from $7.5M in 1996.
How fast is Apyx Medical Corporation growing?
Apyx Medical Corporation (APYX) grew revenue by 9.9% over the past year. This is steady growth.
Is APYX profitable?
Apyx Medical Corporation (APYX) reported a net loss of $9.2M for fiscal year 2025.
Dividend & Returns
What is APYX's return on equity?
Apyx Medical Corporation (APYX) has a return on equity (ROE) of -76.9%. Negative ROE indicates the company is unprofitable.
What is Apyx Medical Corporation's free cash flow?
Apyx Medical Corporation (APYX) had negative free cash flow of $9.0M in fiscal year 2025, likely due to heavy capital investments.